With new and emerging therapies – mostly in oncology and immunology – more high-priced drugs are coming to market, making it increasingly challenging to ensure patient access to these treatments. This influx of high-priced drugs has led to a discussion around whether prescription drug prices should reflect more accurately the level of improvement in patient outcomes. 

To address this, the Institute for Clinical and Economic Review (ICER) launched an international collaboration to develop new methods to guide value-based pricing. This initiative prompted ICON to conduct research on ICER assessments and perceptions on value-based pricing over the past year.

Read our whitepaper for insights on these questions:

• How and when are payers using ICER assessments?
• What degree of influence is ICER’s cost-effectiveness threshold having on coverage and formulary decisions for payers?
• What are current payer’s views on value-based pricing?